Trials / No Longer Available
No Longer AvailableNCT01689376
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Detailed description
This "Managed Access Program" covers the different types of programs in the participating countries (including compassionate use program, named patient program, cohorts e.g. ATU in France, etc).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (BAY73-4506) | 160 mg BAY73-4506, 3 weeks on drug, 1 week off drug |
Timeline
- First posted
- 2012-09-21
- Last updated
- 2016-08-16
Source: ClinicalTrials.gov record NCT01689376. Inclusion in this directory is not an endorsement.